NASDAQ:GENB Generate Biomedicines Q3 2026 Earnings Results & Report $12.68 -0.81 (-6.03%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more. Generate Biomedicines missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.68 versus the -$0.50 consensus estimate, while revenue was $4.22 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Generate Biomedicines EPS ResultsActual EPS-$0.68Consensus EPS -$0.50Beat/MissMissed by -$0.18One Year Ago EPSN/AGenerate Biomedicines Revenue ResultsActual Revenue$4.22 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Generate Biomedicines Q3 2026 Earnings FAQ Did Generate Biomedicines beat earnings estimates for Q3 2026? Generate Biomedicines (NASDAQ:GENB) reported earnings of -$0.68 per share for Q3 2026, missing the consensus estimate of -$0.50. The report was announced on Thursday, November 12, 2026. What was Generate Biomedicines' revenue for Q3 2026? Generate Biomedicines reported revenue of $4.22 million for Q3 2026. Generate Biomedicines Earnings HeadlinesGenerate Biomedicines GENB Q3 2026: Revenue Misses by 46% as Partner Deals Wind Down1 hour ago | 247wallst.comGenerate Biomedicines: Q3 earnings snapshot1 hour ago | msn.comDo NOT Buy SpaceX Until You See “Mission X”A 30-year veteran who called Tesla before it soared 1,216% is spotlighting a company operating in the shadows of SpaceX. BlackRock, Morgan Stanley, JP Morgan and Goldman Sachs are reportedly loading up on its shares. He says the firm holds a breakthrough Elon Musk needs, and it has nothing to do with rockets or satellites. The CEO told employees more details on the Musk relationship are coming in the coming weeks.November 12 at 1:00 AM | StocksToTrade (Ad)Earnings Flash (GENB) Generate Biomedicines, Inc. Reports Q3 Collaboration Revenue $4.2M1 hour ago | marketscreener.comMGenerate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update2 hours ago | globenewswire.comMonte Rosa Therapeutics (NASDAQ:GLUE) vs. Generate Biomedicines (NASDAQ:GENB) Head-To-Head ContrastNovember 11 at 4:15 AM | americanbankingnews.comSee More Generate Biomedicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Generate Biomedicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Generate Biomedicines and other key companies, straight to your email. Email Address About Generate BiomedicinesGenerate Biomedicines (NASDAQ:GENB) is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma. Generate Biomedicines is led by Chief Executive Officer Mike Nally. The company’s research and development activities are based in the United States, while its medicines are intended for patients in markets where they may ultimately receive regulatory approval.View Generate Biomedicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
